House of Lords Science and Technology Committee. Genomic medicine; 2nd report of session 2008–2009. London: House of Lords; 2009.
2.
TarpeyPSSmithRPleasanceE A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation. Nat Genet 2009; 41:535–43. http://dx.doi.org/10.1038/ng.367
3.
WillattLCoxJBarberJ 3q29 microdeletion syndrome: clinical and molecular characterization of a new syndrome. Am J Hum Genet 2005; 77:154–60. http://dx.doi.org/10.1086/431653
4.
GoobieSKnijnenburgJFitzpatrickD Molecular and clinical characterization of de novo and familial cases with microduplication 3q29: guidelines for copy number variation case reporting. Cytogenet Genome Res 2008; 123:65–78. http://dx.doi.org/10.1159/000184693
5.
National Institute for Clinical Excellence. National clinical audit of epilepsy-related death [Internet]. London: NICE; 2002 [cited 2012 jun 21]. Available from: http://www.nice.org.uk/media/94E/3C/epilepsyreport.pdf
6.
ZuberiSM.Chromosome disorders associated with epileptic seizures. In: Panayiotopoulos CP, Benbadis SR, Beran RG et al, editors. Atlas of epilepsies. Springer 2010. pp.121–7. http://dx.doi. org/10.1007/978-1-84882-128-6_17
7.
DepienneCTrouillardOSaint-MartinC Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients. J Med Genet 2009; 46:183–91. http://dx.doi.org/10.1136/jmg.2008.062323
8.
HeronSECoxKGrintonBE Deletions or duplications in KCNQ2 can cause benign familial neonatal seizures. J Med Genet 2007; 44:791–6. http://dx.doi.org/10.1136/jmg.2007.051938
9.
DeprezLWeckhuysenSHolmgrenP Clinical spectrum of early-onset epileptic encephalopathies associated with STXBP1 mutations. Neurology 2010; 75:1159–65. http://dx.doi.org/10.1212/WNL.0b013e3181f4d7bf
10.
ChironCMarchandMCTranA Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000; 356:1638–42. http://dx.doi.org/10.1016/S0140-6736(00)03157-3
11.
KonstantinidouAFryssiraHSifakisS Cranioectodermal dysplasia: a probable ciliopathy. Am J Med Genet A 2009;149A:2206–11. http://dx.doi.org/10.1002/ajmg.a.33013
12.
VissersLEde LigtJGilissenC A de novo paradigm for mental retardation. Nat Genet 2010; 42:1109–12. http://dx.doi.org/10.1038/ng.712
13.
DaviesECGreenCFTaylorS Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient episodes. PLoS One 2009; 4:e4439. http://dx.doi.org/10.1371/journal.pone.0004439
14.
HughesDAVilarFJWardCC Cost-effective analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004; 14:335–42. http://dx.doi.org/10.1097/00008571-200406000-00002
15.
MallalSPhillipsECarosiG HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568–79. http://dx.doi.org/10.1056/NEJMoa070613571-200406000-00002
